Department of Ophthalmology, University Hospital Ulm, 89075, Ulm, Germany.
Department of Ophthalmology, ViDia Christliche Kliniken, 76135, Karlsruhe, Germany.
J Neurol. 2023 Feb;270(2):891-897. doi: 10.1007/s00415-022-11439-7. Epub 2022 Oct 28.
There is no evidence-based therapy for non-arteritic central retinal artery occlusion (NA-CRAO). Intravenous thrombolysis (IVT) with alteplase in a time window < 4.5 h may lead to a favorable outcome. Purpose of this study was to investigate the feasibility, efficacy and safety of IVT in patients classified as functionally blind.
We conducted a retrospective observational study of NA-CRAO-patients. All patients underwent an ophthalmological and neurological examination including cerebral magnetic resonance imaging (MRI) for assessment of additional stroke lesions. Patients were treated either conservatively or with IVT within 4.5 h. Visual acuity (VA) was evaluated in logMAR and a categorical analysis was performed.
Thirty-seven patients were included in the study, 21 patients in the conservative treatment group (CTG) and 16 patients in the IVT group. The median logMAR visual acuity at admission and discharge was similar in both groups. The medium symptom to treatment time in the IVT group was 158.0 min. 3 patients (19%) of the IVT group showed a favorable outcome, all CTG patients remained at the level of functional blindness. No serious adverse events were observed after IVT. MRI showed additional acute stroke in over one-third of the patients (n = 14).
Early intravenous thrombolysis therapy according to the current stroke protocol n a time window up to 4.5 h after the onset of symptoms was feasible and might be a potential treatment option for NA-CRAO. Patients with NA-CRAO are at very high risk of ischemic stroke and MRI should be done in all patients for optimized treatment and secondary stroke prevention. A prospective randomized study is required.
目前尚无针对非动脉炎性中央视网膜动脉阻塞(NA-CRAO)的循证治疗方法。在发病后<4.5 h 的时间窗内使用阿替普酶进行静脉溶栓(IVT)可能会带来良好的结局。本研究旨在探讨将 IVT 应用于功能盲患者的可行性、疗效和安全性。
我们进行了一项回顾性观察性研究,纳入了 NA-CRAO 患者。所有患者均接受眼科和神经科检查,包括脑部磁共振成像(MRI)以评估是否存在其他卒中病灶。患者接受保守治疗或在 4.5 h 内接受 IVT 治疗。采用 logMAR 评估视力,并进行分类分析。
本研究共纳入 37 例患者,其中 21 例接受保守治疗(CTG),16 例接受 IVT 治疗。两组患者入院和出院时的 logMAR 视力中位数相似。IVT 组的中位症状至治疗时间为 158.0 min。IVT 组有 3 例(19%)患者预后良好,所有 CTG 患者仍处于功能盲状态。IVT 后未观察到严重不良事件。MRI 显示超过三分之一的患者(n=14)存在新发急性卒中。
根据当前的卒中治疗方案,在症状出现后 4.5 h 内进行早期静脉溶栓治疗是可行的,可能是 NA-CRAO 的潜在治疗选择。NA-CRAO 患者发生缺血性卒中的风险极高,应在所有患者中进行 MRI 检查,以优化治疗并进行二级卒中预防。需要开展前瞻性随机研究。